Joachim Schwable
Overview
Explore the profile of Joachim Schwable including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann J, Seidl C, et al.
Front Immunol
. 2024 Dec;
15:1413927.
PMID: 39737173
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an...
2.
Semmler A, Kohler J, Regolien L, Bayer F, Polyansky N, Gradhand E, et al.
Curr Res Transl Med
. 2024 Sep;
72(4):103463.
PMID: 39278153
Background: The setting of normovolemic anemia is required for a variety of research applications, such as testing of novel medication for anemia treatment. Unfortunately, large animal models using full blood...
3.
Kugler S, Hahnefeld L, Kloka J, Ginzel S, Nurenberg-Goloub E, Zinn S, et al.
Talanta
. 2023 Oct;
268(Pt 1):125295.
PMID: 37866305
Background: The COVID-19 pandemic challenged the management of technical and human resources in intensive care units (ICU) across the world. Several long-term predictors for COVID-19 disease progression have been discovered....
4.
Epah J, Spohn G, Preiss K, Muller M, Dorr J, Bauer R, et al.
BMC Med
. 2023 Sep;
21(1):360.
PMID: 37726769
Background: Bone marrow (BM) transplantation is a life-saving therapy for hematological diseases, and the BM harbors also highly useful (progenitor) cell types for novel cell therapies manufacture. Yet, the BM...
5.
Korper S, Gruner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, et al.
J Clin Invest
. 2022 Nov;
132(24).
PMID: 36326824
BACKGROUNDResults of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of...
6.
Meumann N, Cabanes-Creus M, Ertelt M, Navarro R, Lucifora J, Yuan Q, et al.
Hepatology
. 2022 Aug;
77(3):802-815.
PMID: 35976053
Background And Aims: Current liver-directed gene therapies look for adeno-associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted...
7.
Sohling N, Leiblein M, Schaible A, Janko M, Schwable J, Seidl C, et al.
Materials (Basel)
. 2020 Jul;
13(14).
PMID: 32668732
Treatment of large bone defects is one of the great challenges in contemporary orthopedic and traumatic surgery. Grafts are necessary to support bone healing. A well-established allograft is demineralized bone...
8.
Miesbach W, Schwable J, Muller M, Seifried E
Dtsch Arztebl Int
. 2019 Dec;
116(47):791-798.
PMID: 31847949
Background: Approximately 4550 persons were under treatment for hemophilia in Germany in 2017. The condition is currently treated with intravenous supplementa- tion of the missing clotting factor, either prophylactically or...
9.
Surun D, Schwable J, Tomasovic A, Ehling R, Stein S, Kurrle N, et al.
Mol Ther Nucleic Acids
. 2018 Mar;
10:1-8.
PMID: 29499925
The CRISPR/Cas9 prokaryotic adaptive immune system and its swift repurposing for genome editing enables modification of any prespecified genomic sequence with unprecedented accuracy and efficiency, including targeted gene repair. We...
10.
Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, et al.
Blood
. 2017 Dec;
131(9):1022-1031.
PMID: 29246900
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate. AMT-060 combines an...